Objective: The purpose of this study was to determine the ex vivo human placental transfer of trovafloxacin from the maternal circulation to the fetal circulation.
rovafloxacin is a broad-spectrum antibacterial fluronaphthyridone related to other synthetic fluroquinolone compounds. There is a paucity of information on the placental transfer and accumulation of quinolone compounds in pregnant women because of the category C risk. The adverse reactions include possible skeletal malformations and increased gestational time. Additional serious adverse reactions in humans include potential hepatic malfunction, tendinitis, and tendon rupture. However, in reported cases of at least 32 women who received quinolone antibiotics in the first trimester of pregnancy, no congenital abnormalities were reported.
1,z The results of these pregnancies were 21 normal births, ectopic pregnancy, 4 spontaneous abortions, 5 terminations, and unknown outcome.
Because little or no information is available on the placental transfer of quinolone compounds, we used our ex vivo human placental model to determine the placental transfer of trovafloxacin.
MATERIALS AND METHODS
Laboratory-standard powder of trovafloxacin was a gift from Pfizer Pharmaceuticals (Groton, CT). The Trovafloxacin was perfused into the isolated cotyledon at concentrations of approximately 1.0 lag/ml and 7.0 lag/ml to represent the trough and peak concentrations of the drug. Four milliliters of maternal and fetal perfusates were collected every 10 min for hr with both the maternal and the fetal circulations open, at which time both the maternal and the fetal circulations were closed and the drug was allowed to accumulate for hr, with samples collected every 10 min as previously described. All samples were frozen at 80C until analysis.
The high-pressure liquid chromatographic (HPLC) assay of trovafloxacin consisted of all water-associated analytical equipment, which consisted of an M45 pump, 712B integrated sample processor, and a 486 variable wavelength detector.
A 10-mm recorder (Linear, Inc., Houston, TX) was used to determine the peak height of the standards and samples. A phenomenex C18 bond-a-clone column was used for compound separation. Other analytical conditions consisted of a sensitivity setting of 0.005 AU, a wavelength of 313 k, a flow rate of 2.0 ml/min, a 50 lal injection, and a mobil phase of 550 ml HzO, 450 ml methanol, and 40 lag/liter of penta sulfonic acid, pH 4.0. Within-batch and between-batch reproducibility studies were performed to validate the assay.
RESULTS
Reproducibility studies for the HPLC determination of trovafloxacin in the perfusates and tissue samples showed 95% reproducibility with a mini- 
